Articles related to NEUROIMAGING

Brain-predicted age difference and socioeconomic status moderated the relationship between AD pathology markers and cognitive performance in a cross-sectional cohort of 621 cognitively unimpaired older adults.

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.

Blarcamesine (Anavex 2-73), an investigational once-daily oral autophagy enhancer, showed sustained cognitive, functional, and brain volume benefits through nearly 3 years in a Phase 2b/3 trial and open-label extension presented at AD/PD 2026.

A retrospective ADNI cohort analysis found that omega-3 supplement users showed faster cognitive decline over 5 years than matched non-users, with FDG-PET evidence of reduced brain glucose metabolism.

Multiple Alzheimer disease biomarkers showed accelerated age-related changes near age 70 in a Mayo Clinic Study of Aging cohort, identifying potential screening and monitoring windows.

In a small neuroimaging substudy of children exposed to prenatal stress during Superstorm Sandy, stronger early adaptive skills were associated with limbic activation patterns resembling unexposed peers.